Jushi Holdings has received DEA registration for select medical cannabis dispensaries, marking the company as among the first multi-state operators to secure federal approval under the agency's new registration framework.
The Pennsylvania-based company announced the registrations cover certain retail facilities operating under state medical cannabis programs. The DEA began issuing registrations to state-licensed cannabis businesses following the Department of Health and Human Services' recommendation to move marijuana from Schedule I to Schedule III.
The registrations represent a significant administrative shift. Until now, state-licensed cannabis operators existed in a legal gray area—compliant with state law but technically violating federal statute. DEA registration provides a measure of federal acknowledgment, though it does not resolve all conflicts between state and federal cannabis policy.
The Registration Process
Jushi operates 39 dispensaries across seven states, including Pennsylvania, Virginia, Illinois, Massachusetts, Nevada, Ohio, and California. The company has not disclosed which specific locations received DEA registration or how many facilities were approved in this initial batch.
The DEA's registration process requires operators to demonstrate compliance with state medical cannabis regulations and meet federal security and record-keeping standards. Companies must maintain detailed inventory tracking and implement protocols that mirror those used for Schedule III controlled substances like ketamine and certain anabolic steroids.
For Jushi, the registrations could provide operational advantages. Federally registered facilities may find it easier to secure banking relationships, as financial institutions have historically cited federal illegality as a barrier to serving cannabis clients. The registrations might also streamline interstate supply chain logistics, though cannabis products themselves cannot legally cross state lines.
What This Means for the Industry
The DEA has not publicly announced how many cannabis operators have applied for or received registrations. Industry analysts estimate hundreds of applications are in the pipeline, with medical cannabis operators likely to receive priority over adult-use businesses.
Jushi's announcement follows the DEA's publication of interim final rules in December that outlined the registration framework. Those rules created a pathway for existing state-licensed operators to obtain federal registration without disrupting their current operations.
But questions remain. The registration process does not address Section 280E of the tax code, which prohibits cannabis businesses from deducting normal business expenses. It also does not resolve conflicts with FDA regulations or provide safe harbor from potential federal enforcement actions.
Looking Ahead
The cannabis industry is watching closely to see how many operators receive DEA registration and whether it translates into tangible business benefits. Some operators have expressed concern about the cost and administrative burden of maintaining dual compliance with both state and federal requirements.
Jushi has not indicated whether it plans to seek DEA registration for its remaining facilities. The company reported $229 million in revenue for the third quarter of 2024, with medical cannabis sales accounting for roughly 60% of total revenue across its footprint.
The DEA's next steps on broader rescheduling remain uncertain. A final rule moving marijuana to Schedule III could take months to implement, with public comment periods and potential legal challenges likely to extend the timeline.
This article is based on original reporting by www.cannabisbusinesstimes.com.
